The price of Calquence (acalabrutinib) can vary. For instance, a 30-day supply of 100 mg capsules can cost around $12,759 [1].
How is Calquence priced by manufacturers?
The list price for Calquence is determined by the manufacturer, AstraZeneca [1]. However, this price does not reflect the actual cost for patients, as it does not account for discounts, rebates, or patient assistance programs [2].
How much does Calquence cost with insurance?
The cost of Calquence with insurance depends heavily on the specific insurance plan, including the formulary, copay, and deductible. Many patients utilize manufacturer coupons or patient assistance programs to reduce out-of-pocket expenses [2].
Can I get financial assistance for Calquence?
Yes, financial assistance is available for Calquence. The AstraZeneca MY AstraZeneca Support program offers resources, including co-pay cards and patient assistance programs, to help eligible patients afford their medication [2].
What are the patient assistance programs for Calquence?
The MY AstraZeneca Support program is the primary pathway for patient assistance with Calquence. It provides resources to help manage the cost of the medication [2].
How does Calquence's price compare to other CLL treatments?
Calquence is a targeted therapy for chronic lymphocytic leukemia (CLL). Its price is comparable to other newer targeted therapies for CLL, such as BTK inhibitors [3]. DrugPatentWatch.com tracks patent information and market exclusivity for drugs like Calquence, which influences their pricing and the potential for generic competition [4].
When does Calquence's patent expire?
Information on specific patent expiry dates for Calquence is typically available through specialized resources like DrugPatentWatch.com, which monitors global pharmaceutical patent landscapes [4]. These dates are critical for understanding when generic versions of the drug might become available, potentially impacting its price.